130 related articles for article (PubMed ID: 12614922)
1. Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease.
Schönknecht P; Pantel J; Hunt A; Volkmann M; Buerger K; Hampel H; Schröder J
Neurosci Lett; 2003 Mar; 339(2):172-4. PubMed ID: 12614922
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia.
Nägga K; Gottfries J; Blennow K; Marcusson J
Dement Geriatr Cogn Disord; 2002; 14(4):183-90. PubMed ID: 12411760
[TBL] [Abstract][Full Text] [Related]
3. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies.
Vanderstichele H; De Vreese K; Blennow K; Andreasen N; Sindic C; Ivanoiu A; Hampel H; Bürger K; Parnetti L; Lanari A; Padovani A; DiLuca M; Bläser M; Olsson AO; Pottel H; Hulstaert F; Vanmechelen E
Clin Chem Lab Med; 2006; 44(12):1472-80. PubMed ID: 17163825
[TBL] [Abstract][Full Text] [Related]
4. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.
Buerger K; Zinkowski R; Teipel SJ; Tapiola T; Arai H; Blennow K; Andreasen N; Hofmann-Kiefer K; DeBernardis J; Kerkman D; McCulloch C; Kohnken R; Padberg F; Pirttilä T; Schapiro MB; Rapoport SI; Möller HJ; Davies P; Hampel H
Arch Neurol; 2002 Aug; 59(8):1267-72. PubMed ID: 12164722
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease.
Ishiguro K; Ohno H; Arai H; Yamaguchi H; Urakami K; Park JM; Sato K; Kohno H; Imahori K
Neurosci Lett; 1999 Jul; 270(2):91-4. PubMed ID: 10462105
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of cerebrospinal fluid phosphorylated tau
Kiđemet-Piskač S; Babić Leko M; Blažeković A; Langer Horvat L; Klepac N; Sonicki Z; Kolenc D; Hof PR; Boban M; Mimica N; Borovečki F; Šimić G
CNS Neurosci Ther; 2018 Aug; 24(8):734-740. PubMed ID: 29453935
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer's disease and vascular dementia.
Ravaglia S; Bini P; Sinforiani E; Franciotta D; Zardini E; Tosca P; Moglia A; Costa A
Neurol Sci; 2008 Dec; 29(6):417-23. PubMed ID: 19011737
[TBL] [Abstract][Full Text] [Related]
8. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group.
Parnetti L; Lanari A; Amici S; Gallai V; Vanmechelen E; Hulstaert F;
Neurol Sci; 2001 Feb; 22(1):77-8. PubMed ID: 11487210
[TBL] [Abstract][Full Text] [Related]
9. Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231.
Buerger K; Zinkowski R; Teipel SJ; Arai H; DeBernardis J; Kerkman D; McCulloch C; Padberg F; Faltraco F; Goernitz A; Tapiola T; Rapoport SI; Pirttilä T; Möller HJ; Hampel H
Am J Psychiatry; 2003 Feb; 160(2):376-9. PubMed ID: 12562590
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S
J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010
[TBL] [Abstract][Full Text] [Related]
11. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S
Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
[TBL] [Abstract][Full Text] [Related]
12. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
[TBL] [Abstract][Full Text] [Related]
13. Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.
Mollenhauer B; Bibl M; Wiltfang J; Steinacker P; Ciesielczyk B; Neubert K; Trenkwalder C; Otto M
Clin Chem Lab Med; 2006; 44(2):192-5. PubMed ID: 16475906
[TBL] [Abstract][Full Text] [Related]
14. Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease.
Buerger K; Otto M; Teipel SJ; Zinkowski R; Blennow K; DeBernardis J; Kerkman D; Schröder J; Schönknecht P; Cepek L; McCulloch C; Möller HJ; Wiltfang J; Kretzschmar H; Hampel H
Neurobiol Aging; 2006 Jan; 27(1):10-5. PubMed ID: 16298235
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia.
de Jong D; Jansen RW; Kremer BP; Verbeek MM
J Gerontol A Biol Sci Med Sci; 2006 Jul; 61(7):755-8. PubMed ID: 16870640
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease.
Kapaki EN; Paraskevas GP; Tzerakis NG; Sfagos C; Seretis A; Kararizou E; Vassilopoulos D
Eur J Neurol; 2007 Feb; 14(2):168-73. PubMed ID: 17250725
[TBL] [Abstract][Full Text] [Related]
17. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.
Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P
J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
[TBL] [Abstract][Full Text] [Related]
20. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients.
Kohnken R; Buerger K; Zinkowski R; Miller C; Kerkman D; DeBernardis J; Shen J; Möller HJ; Davies P; Hampel H
Neurosci Lett; 2000 Jun; 287(3):187-90. PubMed ID: 10863026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
